SXTC — China SXT Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $1.94m
- -$25.23m
- $1.14m
Annual income statement for China SXT Pharmaceuticals, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.6 | 1.97 | 1.93 | 1.74 | 1.14 |
| Cost of Revenue | |||||
| Gross Profit | 1.25 | 0.426 | 0.554 | 0.367 | 0.249 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 7.79 | 7.58 | 4.44 | 4.42 | 8.26 |
| Operating Profit | -5.19 | -5.61 | -2.52 | -2.68 | -7.12 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.41 | -5.93 | -3.1 | -3.3 | -6.21 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -5.74 | -5.93 | -3.1 | -3.3 | -6.21 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.74 | -5.93 | -3.1 | -3.3 | -6.21 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.74 | -5.93 | -3.1 | -3.3 | -6.21 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,321,680,876 | -200,768,584 | -29,597,434 | -1,936,158 | -72,404 |